AMD3100 or its derivatives have been shown to inhibit the migration of CXCR4+ cells into the synovial fluid of RA patients, reduce neovascularisation, and lessen the severity of lupus nephritis in an arthritic mouse model [39]. Here, CXCR4 is linked to rheumatoid arthritis.